News

New positive trial in acute stroke published

Cerebrolysin® enhances treatment safety for acute stroke patients
read more

ESOC 2023, Munich - EVER Symposium

Read the congress report now!
read more
1 21 22 23 24 25 72
24.09.2025

WSC 2025 - Visit us!

World Stroke Congress 2025 | October 22–24 | Barcelona
Read more
16.09.2025

Follow-up on NTSC Extended – 1st Thailand Edition

Bangkok, Thailand – July 3, 2025
Read more
20.08.2025

New video about ESCAS

Cerebrolysin® helps aphasia patients after Stroke
Read more
1 21 22 23 24 25 36
Go to Archive

Congresses

11th European Stroke Organisation Conference

Helsinki, Finland
21 - 23 May 2025
GO TO EVENT

17th World Stroke Congress

Barcelona, Spain
22 - 25 October 2025
GO TO EVENT

Notice to U.S. Visitors

Please be advised that Cerebrolysin is not registered with the U.S. Food and Drug Administration (FDA) and is not approved for sale or distribution in the United States.

Cerebrolysin is a prescription medication for use under the supervision of an authorized health care professional. For any medical inquiries, please consult with a healthcare professional.